1st Counsel – Lifestyle
Author:
GH Research PLC
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
March 25, 2026
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
March 5, 2026